PTC Therapeutics, Inc. announced on November 3, 2026, that its Board of Directors has authorized a share repurchase program allowing the company to repurchase up to $500 million of its outstanding common stock, subject to market conditions.

Key Highlights

  • Repurchase authorization: The Board of Directors authorized repurchases of up to $500 million of the company's outstanding shares of common stock.
  • Market conditions apply: The program is expressly subject to market conditions, according to the announcement.
  • Multiple repurchase methods permitted: The company disclosed that repurchases may be made through open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.
  • Management discretion: Share repurchases may be made from time to time at management's discretion.
  • CEO statement: Chief Executive Officer Matthew B. Klein, M.D., stated the program "reflects our deep conviction in the strength of the Company and the prospects for near- and long-term growth."
  • Financial flexibility noted: The company indicated it intends to "maintain the financial flexibility to support existing programs and pursue potential value creative business development transactions," according to the CEO's statement.

PTC Therapeutics Board Approves $500 Million Common Stock Buyback

PTC Therapeutics, Inc. (NASDAQ:PTCT), headquartered in Warren, N.J., disclosed on November 3, 2026, that its Board of Directors has authorized a new share repurchase program. Under the authorization, PTC may repurchase up to $500 million of its outstanding shares of common stock, subject to market conditions, the company disclosed.

According to the filing, share repurchases under the program may be executed through a variety of methods, including open-market transactions such as pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions conducted in accordance with applicable securities laws. The timing and amount of any repurchases are subject to management's discretion.

The company's CEO, Matthew B. Klein, M.D., characterized the authorization as reflecting conviction in the company's strength and growth prospects, while also stating that PTC intends to maintain financial flexibility for existing programs and potential business development transactions. The press release contains forward-looking statements, which the company noted are subject to risks and uncertainties described in its most recent Annual Report on Form 10-K and other regulatory filings. PTC stated it does not undertake to update forward-looking statements except as required by law.

What Was Disclosed

PTC Therapeutics disclosed a Board-authorized share repurchase program of up to $500 million in outstanding common stock, subject to market conditions, with repurchases to be made at management's discretion using multiple transaction methods permitted under applicable securities laws.